How Abbott is making good on investor promises

Abbott (NYSE: ABT) has won FDA approval of MR-compatible ICDs – an indication that it could be making good executing on key priorities it inherited when it acquired St. Jude Medical for $25 billion early this year. The news today “lends incremental credibility to our thesis that ABT can and will have a positive impact on STJ

Abbott heart device shown safe for infants

Developing very small devices that can be used for children is a significant challenge in the market. FDA is cautious to approve new devices into this market for vulnerable patients. But the efforts are needed to improve the health of babies, particularly those born with heart defects. Abbott’s reduced sized Amplatzer duct occluder II (ADO

Deaths prompt Abbott recall of Thoratec HeartMate II controllers

Brad Perriello, Executive Editor Abbott (NYSE:ABT) is recalling nearly 29,000 controllers for the HeartMate II implantable heart pump made by its Thoratec subsidiary after 26 patients died trying to change out the controllers on their own. The March 29 recall of 28,882 controllers for the HeartMate II left ventricular assist device follows 70 reports of

These big medtech names performed the best in early 2017

Fink Densford, Associate Editor and Chris Newmarker, Managing Editor This year so far has been an especially good one for medical device company stocks. More than four-fifths of the world’s 100 largest medical device companies saw their stock values increase during the first quarter of 2017 – about half enjoyed double-digit percentage increases, according to an analysis

Pages: 1 2 3 4 5 6 7 8

The top medtech stories of early 2017

The new Trump administration and Republican Congress – and all the accompanying change and uncertainty –is the major story for the medical device industry. But there are many other medtech stories worth noting from the first quarter of 2017. There was an FDA warning over Abbott’s Absorb bioresorbable stent, a continued spate of M&A deals, a

Pages: 1 2 3 4 5 6